Clinical research
Despite hitting endpoints in the late-stage trial, BioCryst’s BCX7353 results do not stack up against Takeda’s Takhzyro, which was approved last year.
Germany-based Boehringer Ingelheim announced that its SENSCIS Phase III clinical trial met its primary endpoint, which was reduction in the annual rate of decline in forced vital capacity.
Merck & Co. announced that its Keytruda failed to hit its primary endpoint in the Phase III Keynote-119 clinical trial. The primary endpoint was superior overall survival compared to chemotherapy.
Medigene AG, a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies, will present data from the interim analysis of the ongoing Phase I / II clinical trial with Medigene’s DC vaccine during the annual congress of the European Hematology Association taking place from 13 - 16 June in Amsterdam.
Cristal Therapeutics, a clinical-stage pharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases with high unmet patient need, today announced three upcoming poster presentations that highlight CPC634 positive data from its three phase 1 safety and biodistribution studies at the ASCO 2019 meeting, Chicago, Illinois May 31st - June 4th.
Here’s a roundup of some of the top clinical trial news from the previous week.
An Independent Data Monitoring Committee recommended the trial be stopped because of lack of survival benefit for patients receiving the drug compared to placebo.
Patients were randomized 1:1 to receive Nerlynx and Xeloda or Tykerb and Xeloda. Co-primary endpoints were progression-free survival and overall survival.
Primary analysis of L-MIND trial of tafasitamab (MOR208) plus lenalidomide in relapsed or refractory (r/r) DLBCL confirms overall strong data reported previously from this trial
MorphoSys AG today announced results from the primary analysis (cut-off date November 30, 2018) of the ongoing single-arm phase 2 clinical trial known as L-MIND.
PRESS RELEASES